Tackling the Tuberculosis Burden in Children: A Global Perspective

By Crystal Lubbe

March 12, 2025

Did you know the global burden of tuberculosis (TB) among children has dropped significantly over the past three decades? A recently published article analyses the global tuberculosis burden children face. It details the situation from 1990 to 2021 using data from the Global Burden of Disease Study 2021. The report shows a significant decrease in TB incidence, mortality, and disability-adjusted life years (DALYs) over this period. However, regional and socioeconomic disparities remain notable. Despite progress, tuberculosis continues to pose a major public health threat, especially in areas with a low socio-demographic index (SDI).

Key Insights

  • Decline in TB Burden: The global TB incidence among children and adolescents decreased by 37.4% from 1990 to 2021. Deaths also dropped by 71.7%.
  • Regional Disparities: Regions with low SDI, such as parts of Africa, still face a high tuberculosis burden in children disproportionately. High-income regions, however, have seen substantial reductions.
  • Sex Differences: Females under 20 have higher age-standardised incidence rates (ASIR), mortality rates (ASMR), and DALY rates compared to males.
  • Drug Resistance: Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) among children and adolescents are growing concerns.

Background Context

The World Health Organization (WHO) is working to end TB through its End TB Strategy. This strategy aims to reduce TB incidence and mortality by defined targets. Progress has been slow, especially in children and adolescents, where TB remains a major cause of morbidity and mortality. The COVID-19 pandemic has further complicated TB control efforts. It disrupted healthcare services and led to underreporting of TB cases. For detailed analysis, see here.

Implications

The findings have important implications for health economics and outcomes research:

  • Healthcare Infrastructure: Investing in healthcare infrastructure, especially in low SDI regions, is crucial for improving TB diagnosis and treatment.
  • Socioeconomic Interventions: Addressing factors like poverty and malnutrition can help reduce TB transmission.
  • Drug Resistance Management: Effective strategies are needed to manage drug-resistant TB and prevent its spread among vulnerable populations.
  • Research and Development: More research into pediatric TB diagnostic tools and treatment formulations is urgently needed to improve outcomes for children and adolescents.
Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.